Open-label Study of Nelotanserin in Lewy Body Dementia With Visual Hallucinations or REM Sleep Behavior Disorder
NCT ID: NCT02871427
Last Updated: 2019-03-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE2
80 participants
INTERVENTIONAL
2016-10-20
2019-01-17
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study Evaluating Nelotanserin for Treatment of Visual Hallucinations in Subjects With Lewy Body Dementia
NCT02640729
"Pilot Study of Armodafinil in Patients With Dementia With Lewy Bodies"
NCT01023672
Safety and Efficacy of Galantamine in Patients With Dementia With Lewy Bodies
NCT00230997
Distinguishing Between Alzheimer's Disease, Lewy Body Dementia, and Parkinson's Disease
NCT03019757
Study of LM11A-31-BHS in Mild-moderate AD Patients
NCT03069014
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Nelotanserin
Once Daily, Oral, at 20, 40, 60, or 80 mg dose
Nelotanserin
Once Daily, Oral, at 20, 40, 60, or 80 mg dose
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Nelotanserin
Once Daily, Oral, at 20, 40, 60, or 80 mg dose
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
50 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Axovant Sciences Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ilise Lombardo, MD
Role: STUDY_DIRECTOR
Axovant Sciences, Inc., Clinical Research
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
US120
Birmingham, Alabama, United States
US143
Little Rock, Arkansas, United States
US114
Boca Raton, Florida, United States
US180
Maitland, Florida, United States
US154
Ocala, Florida, United States
US113
Orlando, Florida, United States
US152
Ormond Beach, Florida, United States
US107
Indianapolis, Indiana, United States
US132
Lenexa, Kansas, United States
US103
Rochester, Minnesota, United States
US129
Lincoln, Nebraska, United States
US101
Chapel Hill, North Carolina, United States
US147
Fargo, North Dakota, United States
US111
Cincinnati, Ohio, United States
US104
Cleveland, Ohio, United States
US105
Columbus, Ohio, United States
US173
Lincoln, Rhode Island, United States
US128
Memphis, Tennessee, United States
US131
San Antonio, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RVT-102-2003
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.